TRAIL/CD253 Monoklonaler Antikörper

TRAIL/CD253 Monoklonal Antikörper für WB, IHC, ELISA

Wirt / Isotyp

Maus / IgG1

Getestete Reaktivität

human

Anwendung

WB, IHC, IF, ELISA

Konjugation

Unkonjugiert

Publikationen(3)

CloneNo.

1B9B4

Kat-Nr. : 66756-1-Ig

Synonyme

TNFSF10, TRAIL, 1B9B4, Apo-2 ligand, CD253

---

• 

  WB analysis of human milk using 66756-1-Ig

  human milk were subjected to SDS PAGE followed by western blot with 66756-1-Ig (TRAIL antibody) at dilution of 1:2000 incubated at room temperature for 1.5 hours.

• 

  IHC staining of human tonsillitis using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human tonsillitis using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human tonsillitis tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 10x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

• 

  IHC staining of human prostate cancer using 66756-1-Ig

  Immunohistochemical analysis of paraffin-embedded human prostate cancer tissue slide using 66756-1-Ig (TRAIL antibody) at dilution of 1:200 (under 40x lens). Heat mediated antigen retrieval with Tris-EDTA buffer (pH 9.0).

---

Geprüfte Anwendungen

• Erfolgreiche Detektion in WB: humanes Milch-Gewebe
• Erfolgreiche Detektion in IHC: humanes Tonsillitisgewebe, humanes Prostatakarzinomgewebe; Hinweis: Antigendemaskierung mit TE-Puffer pH 9,0 empfohlen. (*) Wahlweise kann die Antigendemaskierung auch mit Citratpuffer pH 6,0 erfolgen.

Empfohlene Verdünnung

• Western Blot (WB): WB : 1:500-1:2000
• Immunhistochemie (IHC): IHC : 1:50-1:500

It is recommended that this reagent should be titrated in each testing system to obtain optimal results.

Sample-dependent, check data in validation data gallery

Veröffentlichte Anwendungen

• WB: See 1 publications below
• IF: See 1 publications below

Produktinformation

66756-1-Ig bindet in WB, IHC, IF, ELISA TRAIL/CD253 und zeigt Reaktivität mit human

• Getestete Reaktivität: human
• In Publikationen genannte Reaktivität: human
• Wirt / Isotyp: Maus / IgG1
• Klonalität: Monoklonal
• Typ: Antikörper
• Immunogen: TRAIL/CD253 fusion protein Ag25746
• Vollständiger Name: tumor necrosis factor (ligand) superfamily, member 10
• Berechnetes Molekulargewicht: 281 aa, 33 kDa
• Beobachtetes Molekulargewicht: 28-30 kDa
• GenBank-Zugangsnummer: BC032722
• Gene symbol: TRAIL
• Gene ID (NCBI): 8743
• Konjugation: Unkonjugiert
• Form: Liquid
• Reinigungsmethode: Protein-G-Reinigung
• Lagerungspuffer: PBS with 0.02% sodium azide and 50% glycerol
• Lagerungsbedingungen: Bei -20°C lagern. Nach dem Versand ein Jahr lang stabil Aliquotieren ist bei -20^oC Lagerung nicht notwendig. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

TNFSF10/TRAIL (tumor necrosis factor superfamily member 10) is a typical death ligand expressed on natural killer cells and cytotoxic T lymphocytes. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. TNFSF10 induces apoptotic cell death in cancer by binding to its functional death receptors, death receptor (DR) 4 (TNFRSF10A/TRAIL-R1) and DR5 (TNFRSF10B/TRAIL-R2) to activate the extrinsic apoptosis pathway. TRAIL also activates c-Jun N-terminal kinase (MAPK8/JNK) and the transcription factor nuclear factor-κB (NFκB). The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3.

Publikationen

Species	Application	Title
human		Adv Healthc Mater; TRAIL-Armed ER Nanosomes Induce Drastically Enhanced Apoptosis in Resistant Tumor in Combination with the Antagonist of IAPs (AZD5582).; Authors - Huan Hou
human	WB	Cancers (Basel); Extracellular Vesicle Delivery of TRAIL Eradicates Resistant Tumor Growth in Combination with CDK Inhibition by Dinaciclib.; Authors - Changhong Ke
human	IF	Front Bioeng Biotechnol; The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma; Authors - Tian Xue